9 reports of this reaction
1.8% of all ATROPA BELLADONNA reports
#11 most reported adverse reaction
DYSPNOEA is the #11 most commonly reported adverse reaction for ATROPA BELLADONNA. There are 9 FDA adverse event reports linking ATROPA BELLADONNA to DYSPNOEA. This represents approximately 1.8% of all 489 adverse event reports for this drug.
Patients taking ATROPA BELLADONNA who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for ATROPA BELLADONNA, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for ATROPA BELLADONNA:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 9 FDA reports for ATROPA BELLADONNA. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 1.8% of all adverse event reports for ATROPA BELLADONNA, making it a notable side effect.
If you experience dyspnoea while taking ATROPA BELLADONNA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.